Physician profile
Anna P Hall
NPI 1295398717
$1,866.54
in general payments reported to CMS, 2019-2025
29 companies · $251 in 2025
The $251 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $436 · 2022: $968 · 2023: $125 · 2024: $86.57 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $462.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $422.15 | 2021-2023 | Rybelsus, Ozempic |
| Abbvie INC. | $362.10 | 2021-2024 | |
| Glaxosmithkline, LLC. | $115.96 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $110.83 | 2021-2024 | Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $94.95 | 2025 | |
| Pfizer INC. | $88.05 | 2023-2025 | |
| Lilly USA, LLC | $65.77 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $63.04 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $62.14 | 2022-2023 | |
| Mylan Specialty L.P. | $50.18 | 2022 | |
| Corcept Therapeutics | $44.42 | 2022 | |
| Abiomed | $43.21 | 2025 | |
| Antares Pharma, INC. | $35.08 | 2022 | |
| Acerus Pharmaceuticals Corporation | $33.89 | 2021-2022 | |
| Shockwave Medical, INC | $27.22 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.71 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $23.78 | 2021 | |
| Avanir Pharmaceuticals, INC. | $21.74 | 2021 | |
| Amgen INC. | $20.54 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $19.85 | 2022 | |
| Eisai INC. | $19.07 | 2021 | |
| Tactile Systems Technology INC | $17.13 | 2021 | |
| Sumitomo Pharma America, INC. | $16.12 | 2025 | Gemtesa |
| Bausch Health US, LLC | $15.86 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.45 | 2023 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $14.87 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $13.58 | 2022 | |
| Ibsa Pharma INC. | $13.55 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.